This week, four Pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
This week, Repros Therapeutics (NASDAQ:RPRX) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Johnson & Johnson (NYSE:JNJ) earns an A this week, jumping up from last week’s grade of B. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
This week, Bristol-Myers Squibb (NYSE:BMY) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.
Watson Pharmaceuticals (NYSE:WPI) shows solid improvement this week. The company’s rating rises from a B to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.